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Superoxide (O2−•) has been implicated in the pathogenesis of many human diseases including hy-
pertension. Mitochondria-targeted superoxide scavenger mitoTEMPO reduces blood pressure; however,
the structure–functional relationships in antihypertensive effect of mitochondria-targeted nitroxides
remain unclear. The nitroxides are known to undergo bioreduction into hydroxylamine derivatives which
reacts with O2−• with much lower rate. The nitroxides of pyrrolidine series (proxyls) are much more
resistant to bioreduction compared to TEMPOL derivatives suggesting that mitochondria-targeted
proxyls can be effective antioxidants with antihypertensive activity. In this work we have designed and
studied two new pyrrolidine mitochondria targeted nitroxides: 3-[2-(triphenyphosphonio)acetamido]-
and 3-[2-(triphenyphosphonio) acetamidomethyl]-2,2,5,5-tetramethylpyrrolidine-1-oxyl (mCP2) and
(mCP1). These new mitochondria targeted nitroxides have 3- to 7-fold lower rate constants of the re-
action with O2
−• compared with mitoTEMPO; however, the cellular bioreduction of mCP1 and mCP2 was
3- and 2-fold slower. As a consequence incubation with cells afforded much higher intracellular con-
centration of mCP1 and mCP2 nitroxides compared to mitoTEMPO nitroxide. This has compensated for
the difference in the rate of O2
−• scavenging and all nitroxides similarly protected mitochondrial re-
spiration in H2O2 treated endothelial cells. Treatment of hypertensive mice with mCP1 and mCP2
(1.4 mg/kg/day) after onset of angiotensin II-induced hypertension signiﬁcantly reduced blood pressure
to 13375 mmHg and 12976 mmHg compared to 16375 mmHg in mice infused with angiotensin II
alone. mCP1 and mCP2 reduced vascular O2
−• and prevented decrease of endothelial nitric oxide pro-
duction. These data indicate that resistance to bioreduction play signiﬁcant role in antioxidant activity of
nitroxides. Studies of nitroxide analogs such as mCP1 and mCP2 may help in optimization of chemical
structure of mitochondria-targeted nitroxides for improved efﬁcacy and pharmacokinetics of these drugs
in treatment of hypertension and many other conditions including atherosclerosis, diabetes and de-
generative neurological disorders in which mitochondrial oxidative stress seems to play a role.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Clinical data show that 26% of adult population has hypertension
[1]. This disease represents a major risk factor for stroke, myocardial
infarction, and heart failure [2]. Hypertension is a multifactorial dis-
order involving perturbations of the vasculature, the kidney and the
central nervous system [3]. Despite treatment with multiple drugs,
37% of hypertensive patients remain hypertensive [4], likely due to
the mechanisms contributing to blood pressure elevation that are not
affected by current treatments. New classes of antihypertensive
agents could therefore add to the currently available therapeutic ar-
mamentarium to improve treatment of hypertension.B.V. This is an open access article u
cology, VUMC, 2200 Pierce
I. Dikalov).In the past decade it has become clear that vascular superoxide
(O2−•) production contributes to hypertension [5]. In almost all
experimental models of hypertension O2
−• production is increased
in multiple organs, including vasculature where O2−• promote
vasoconstriction and remodeling, increasing systemic vascular
resistance. In the past several years, we have shown that the mi-
tochondria become dysfunctional in hypertension and have de-
ﬁned novel role of mitochondrial O2−• in this disease [6,7]. The
mitochondria are an important source of O2−• and we have shown
that scavenging mitochondrial O2−• improves endothelial function
and attenuates hypertension [6].
Common antioxidants like ascorbate and vitamin E have pro-
ven ineffective in preventing cardiovascular diseases and hy-
pertension [8]. These agents unlikely reach important sites of ROS
production such as the mitochondria. Experimental studies have
shown an important role of mitochondrial reactive oxygen species
in the development of endothelial dysfunction, hypertension andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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expression attenuates hypertension and treatment of hypertensive
mice with mitochondria-targeted antioxidants reduces blood
pressure [6,7].
The membrane potential of mitochondria within living cells is
negative inside (140 mV). As this membrane potential is far
larger than in other organelles within cells, lipophilic cations such
as triphenylphosphonium (TPP) selectively accumulate within
mitochondria [11]. Antioxidants conjugated to TPP, therefore can
be targeted to mitochondria and may be concentrated in the mi-
tochondrial matrix by 1000-fold [12]. The pharmacology of mi-
tochondria-targeted antioxidants is not well understood. For ex-
ample, previously described mitoquinone (MitoQ10) [12] may have
prooxidant and proapoptotic properties due to redox cycling and
generation of O2−• by quinone [13,14]. Nitroxides are well-known
SOD mimetics [15,16]. They are not consumed in the reaction of
superoxide dismutation, and this makes their use advantageous
over many other antioxidants. Nitroxides have very low toxicity
and this makes them perfect candidates for conjugation with li-
pophilic cations (e.g., triphenylmethylphosphonium) for in vivo
use [17]. Furthermore, some phosphonium ions may inhibit oxi-
dation of pyruvate, malate, 2-oxoglutarate and glutamate in heart
mitochondria at micromolar concentrations [18] suggesting that
triphenylmethylphosphonium conjugates should be used at sub-
micromolar concentrations and tested for side effect on respira-
tion. Indeed, low doses of mitoTEMPO did not affect mitochondrial
respiration in control cells but improved mitochondrial function in
the presence of angiotensin II [6].
Recently, it has been shown that pretreatment of endothelial
cells with the mitochondria-targeted SOD mimetic Mito-CP sig-
niﬁcantly reduces H2O2- and lipid peroxide-induced cellular oxi-
dative stress [19]. Mito-CP inhibits peroxide-induced inactivation
of complex I and aconitase, while restoring the mitochondrial
membrane potential. In contrast, the “untargeted” carboxy proxyl
(CP) did not protect the cells from peroxide-induced oxidative
stress and apoptosis. However, in Mito-CP nitroxide is connected
to triphenylmethylphosphonium cation via ester spacer and ester
group can be potentially hydrolyzed to give inactive 3-carbox-
yproxyl (CP).
The main disadvantage of nitroxides is their rapid reduction
with cellular antioxidants and enzymatic systems. For example,
mitoTEMPO is readily reduced in mitochondria to corresponding
hydroxylamine [20]. Hydroxylamine derivatives react with O2−•
much slower compared with nitroxides [6] therefore bioreduction
of nitroxides can signiﬁcantly reduce antioxidant potentials of
nitroxides.
We have hypothesized that increased resistance to bioreduc-
tion will be beneﬁcial to mitochondria-targeted nitroxides. The
structure-functional relationships in antioxidant properties of
mitochondria-targeted nitroxides however remain unclear. In this
work we have designed and studied two new pyrrolidine mi-
tochondria targeted nitroxides. The nitroxides of pyrrolidine series
(proxyls) are weaker oxidants as compared to TEMPOL derivatives,N
O
P
N
H
O
N
O
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O
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+
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Fig. 1. Structures of mitochonand they demonstrate higher stability in biological samples [21].
We hypothesized that mitochondria targeted proxyl derivatives
are much more resistant to bioreduction compared to TEMPOL and
this may improve antioxidant and antihypertensive properties of
new nitroxide derivatives. In this work we have designed two new
pyrrolidine mitochondria targeted nitroxides mCP1 and mCP1
(Fig. 1), and studied their antioxidant properties, cellular accu-
mulation, their bioreduction and antihypertensive properties.Materials and methods
Reagents
Xanthine oxidase was purchased from Roche Molecular Bio-
chemicals (Indianapolis, IN). All other reagents were obtained
from Sigma (St Louis, MO).
Synthesis of mCP1 and mCP2
3-Amino-PROXYL (1a) and 3-aminomethyl-PROXYL (1b) were
prepared according to the literature methods described by Ro-
zantsev and Hankowsky [22,23]. The nitroxides mCP1 and mCP2
were synthesized according to Fig. 2 similarly to the procedure
previously described for mitoTEMPO (mT) [24].
3-((2-Chloroacetamido)methyl)-2,2,5,5-tetramethylpyrrolidin-1-
oxyl (2b). A solution of 3-aminomethyl-PROXYL (0.9 g or 0.005 mol)
and dry triethylamine (1.7 ml or 0.0117 mol) in dry chloroform (20 ml)
was placed into 50 ml ﬂat-bottom ﬂask and cooled to  5 °C. The cold
solution was placed into ice bath and chloroacetyl chloride (0.42 ml or
0.005 mol) was added dropwise upon stirring. The resulting dark
solution was washed with water (3  5 ml), and dried with MgSO4.
The chloroformwas removed under reduced pressure and the residue
was separated by column chromatography (Kieselgel 60, Merck, eluent
chloroform) to give 2b. Yellow oil, Found: С, 53.06; Н, 8.08; N, 11.56;
Cl 14.10. Calculated for C11H2ON2O2Cl: C, 53.33; H, 8.14; N, 11.31; Cl
14.31 %; νmax (KBr)/см1 3306 br, 3084 br, 2972, 2934, 2872, 1668,
1543, 1462, 1364, 1313, 1252, 1178, 1159, 1107, 1057, 789, 764, 691 br,
600, 571, 525, 476.
Similarly, 3-(2-chloroacetamido)-2,2,5,5-tetramethylpyrroli
din-1-oxyl (2a) have been prepared from 3-amino-PROXYL (1a),
(this compound was ﬁrst described in [Mao-Man-Jun; Tian, Xuan;
Chen, Yao-Zu; Gaodeng Xuexiao Huaxue Xuebao (1998), 19(3),
395–398.], but this publication is not available to authors): yellow
crystals, m.p. 130–131°С (hexane-ethyl acetate). Found: С, 51.31;
Н, 7.66; N, 11.87; Cl 15.10. Calculated for C10H18N2O2Cl: C, 51.30; H,
7.76; N, 11.99; Cl 15.17 %; νmax (KBr)/см1 3319, 3076 br, 2982,
2938, 2876, 1676, 1553, 1485, 1408, 1366, 1331, 1299, 1259, 1229,
1196, 1165, 1111, 1045, 806, 772, 687 br, 572, 555, 547, 530, 500.
3-[(2-(Triphenyphosphonio)acetamido)methyl]-2,2,5,5-tetra-
methylpyrrolidin-1-oxyl (mCP1). The 2b (1 g, 0.004 mol) was
placed into 50 ml ﬂask containing toluene (15 ml) and triphenyl-
phosphine (2.7 g, 0.01 mol). The mixture was heated to reﬂux
under nitrogen for 15 hours and then cooled in ice bath theP
N
O
HN
O
P
mitoTEMPO
++
dria-targeted nitroxides.
Fig. 2. Synthesis of proxyl-based mitochondria-targeted nitroxides mCP1 and mCP2.
A.E. Dikalova et al. / Redox Biology 4 (2015) 355–362 357precipitate was separated, washed with toluene and puriﬁed using
column chromatography (silica gel, eluent chloroform-ethanol
50:1). Further puriﬁcation can be performed by following proce-
dure: the compound was dissolving in chloroform, the solvent was
removed under reduced pressure, the resin-like residue was ra-
pidly dissolved in boiling toluene and ﬁltered, the crystalline
precipitate formed was ﬁltered off, washed with toluene and
dried. The overall yield from 1b was 1.3 g (51 %). Pale yellowish
crystals m.p. 236–240°С. Found: С, 68.01; Н, 6.80; N, 5.50; Cl
6.96; P 5.70. Calculated for C29H35N2O2ClP: C, 68.29; H, 6.92; N,
5.49; Cl 6.95; P 6.07 %; νmax (KBr)/см1 3424 br, 3158 br, 2974,
2928, 2874, 1669, 1560, 1484, 1460, 1438, 1397, 1362, 1324, 1146,
1112, 756, 738, 716.
Similarly, 3-(2-(triphenyphosphonio)acetamido)-2,2,5,5-tetra-
methylpyrrolidin-1-oxyl (mCP2) was prepared from 2a: the
overall yield from 1a was 1.7 g (60 %). Pale yellowish crystals m.p.
211–214 °С. Found: С, 68.05; Н, 6.71; N, 5.62; Cl 7.65; P 6.19.
Calculated for C28H33N2O2ClP: C, 67.80; H, 6.71; N, 5.65; Cl 7.15; P
6.24 %; νmax (KBr)/см1 3425 br, 3182 br, 2974, 2883, 2772, 1670,
1558, 1439, 1365, 1330, 1112, 748, 720, 690, 508, 483.
Cell culture
Human aortic endothelial cells (HAEC) were purchased from
Lonza (Chicago, IL) and cultured in EGM-2 medium supplemented
with 2% FBS but without antibiotics. On the day before the study,
the FBS concentration was reduced to 1%. Cells were washed with
Krebs-Hepes buffer prior experiments. Cellular accumulation of
mitochondria-targeted nitroxides was determined by EPR analysis
of cellular pellet following 70 minutes incubation of HAEC with
0.1 mM nitroxide solution in Krebs-Hepes buffer at 37 °C. Cells
were collected by centrifugation at 2500 G for 10 minutes at 4 °C
and transferred into 50 ml capillary tube for immediate EPR ana-
lysis. Concentration of nitroxide in cell pellet was compared with
initial nitroxide level in buffer. Cellular reduction of nitroxides into
EPR silent hydroxylamine was measured by ﬂowing time-depen-
dent decay of nitroxide EPR signal in the cellular pellet. In order to
test the antioxidant protection of mitochondrial function we pre-
incubated HAEC with various concentrations of nitroxides for
15 minutes and then treated with 0.1 mM H2O2 or saline as a
vehicle. Mitochondrial respiration was measured after additional
60 minutes incubation in cellular pellet placed in 0.25 ml Krebs-
Hepes buffer using Clark electrode (Oxygraph, Hanstech).
Animal experiments
Hypertension was induced by angiotensin II (0.7 mg/kg/day) as
described previously [25] using 2–3 month old male C57Bl/6J
mice. Seven days after saline or angiotensin II minipump place-
ment, mice received a second minipump for infusion of saline as
vehicle, mCP1 or mCP2 as described in the ﬁgure legend. Blood
pressure was monitored using either the tail cuff method or
telemetry as previously described [26,27]. All procedures were
performed according to guidelines and approved by IACUC at
Vanderbilt University.ESR experiments
All ESR samples were placed in 50-ml glass capillaries (Corning,
New York, NY). ESR spectra were recorded using an EMX ESR
spectrometer (Bruker Biospin Corp., Billerica, MA) and a super
high Q microwave cavity at room temperature. The ESR settings
for ﬁeld-scan experiments with the spin probe CAT1H were as
follows: ﬁeld sweep, 70 G; microwave frequency, 9.82 GHz; mi-
crowave power, 20 mW; modulation amplitude, 0.7 G; conversion
time, 41 ms; time constant, 164 ms; and receiver gain, 1  105
(n ¼ 4 scans). The rates of H2O2 production were determined by
monitoring the amplitude of the low ﬁeld component of the ESR
spectrum of CAT1-nitroxide with the following settings: ﬁeld
sweep, 60 G; microwave frequency, 9.46 GHz; microwave power,
20 mW; modulation amplitude, 2 G; conversion time, 1311 ms;
time constant, 5243 ms; and receiver gain, 1  105. ESR experi-
ments were repeated at least three times.
Statistics
Experiments were analyzed using the Student Neuman Keuls
post-hoc test and analysis of variance (ANOVA). P levels o 0.05
were considered signiﬁcant.Results
Synthesis and physical properties of mCP1 and mCP2
In this work we have developed synthesis of two new pyrro-
lidine mitochondria targeted nitroxides (Fig. 2). The nitroxides
mCP1 and mCP2 were synthesized from 3-amino- and 3-amino-
methyl-proxyls via chloroacetylation and treatment with triphe-
nylphosphine according to the general Scheme 1 in analogy to the
procedure previously described for mitoTEMPO (mT) [24].
Reaction of O2−• with mCP1 and mCP2
We have investigated reaction of O2−• with mitochondria tar-
geted nitroxides using xanthine oxidase O2−• generating system
and cytochrome c as was previously described by Murphy et al.
[28] Cytochrome c is rapidly reduced by O2−• into ferrocytochrome
c (8  105 M1/s) [29] and this reaction is inhibited in the pre-
sence of nitroxide radicals. Indeed, O2−• mediated cytochrome c
reduction was inhibited in dose-dependent manner in the pre-
sence of mCP1, mCP2 and mitoTEMPO (Fig. 3A). The rate constants
of O2−• reaction with nitroxides were estimated from the linear
regression of inhibition of cytochrome c reduction (Fig. 3B) ex-
pressed as (Vo/V-1), where V and Vo are the rates of cytochrome c
reduction in the presence or absence of nitroxide. The slope of this
linear regression is proportional to the rate constants of O2−• re-
action with nitroxides. The sharpest slope for mitoTEMPO in-
dicates the highest rate of reaction with O2−• compared with mCP1
and mCP2. Taking into account the concentration of cytochrome c
(50 mM) we have estimated the nitroxide rate constants as
y = 0.0062x
y = 0.0019x
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3.2  104 M1/s (mCP2). These data support fast reaction be-
tween new mitochondria targeted nitroxides and O2−•, however
mCP1 and mCP2 react with O2−• by 3- and 7-fold slower compared
with mitoTEMPO.
Cellular accumulation and protection of mitochondrial respiration by
mCP1 and mCP2
We have previously shown rapid accumulation of mitoTEMPO
in intact endothelial cells [6]. In this work we have compared
cellular accumulation of mCP1, mCP2, mitoTEMPO and its un-
targeted analog TEMPOL. EPR analysis of intact HAEC incubated
with 5 mM nitroxides showed signiﬁcant increase in nitroxide ac-
cumulation in cellular pellet. It was found that cellular level of
mCP1 and mCP2 was increased by 37-fold compared with extra-
cellular nitroxide concentration (Fig. 4A). Cellular accumulation of
mitoTEMPO was 25-fold while concentration of untargeted TEMPO0
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To estimate the protective activity of the new mitochondria
targeted proxyl nitroxides we studied their effect on HAEC under
H2O2-induced mitochondrial oxidative stress recently described by
Kalyanaraman group [19]. We have previously shown that H2O2
stimulates production of mitochondrial O2−• [7] and therefore O2−•
scavengers should protect mitochondria. Indeed, it was found that
treatment of intact HEAC with low dose of H2O2 reduced mi-
tochondrial respiration by 2.4-fold while supplementation with
mCP1, mCP2 and mitoTEMPO protected respiration in a dose-de-
pendent manner (Fig. 4B). Mito-TEMPO was more efﬁcient at low
concentration (30 nM) compared with mCP1 and mCP2 which
likely due to higher reactivity of mitoTEMPO with O2−•. However,
higher doses of nitroxides (100 nM) showed similar protection of
cellular respiration.mCP1 mCP1 mCP2 mCP2 mT
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Nitroxides can be susceptible to bioreduction into EPR silent
hydroxylamine form [20]. The increased resistance to bioreduction
may contribute to higher cellular level of mCP1 and mCP2 com-
pared with mitoTEMPO (Fig. 5A). We therefore investigated bior-
eduction of mitochondria targeted nitroxides. It was found that
incubation of in intact endothelial cells with mitoTEMPO for
40 minutes reduced intensity of EPR spectra by 41%. Interestingly,
incubation mCP1 and mCP2 reduced EPR signals by 13% and 18%,
correspondingly (Fig. 5A). Analysis of EPR spectra showed that the
reduction rates of mCP1 and mCP2 were 2–3-fold slower com-
pared with mitoTEMPO (Fig. 4B). These data are in line with higher
resistance to reduction of proxyl nitroxides compared to TEMPO
derivatives.
In vivo treatment with mCP1 and mCP2 after onset of hypertension
Increased vascular O2−• production has been implicated in the
pathogenesis of endothelial dysfunction and hypertension [30,31].
We have previously shown that mitoTEMPO supplementation at-
tenuates development of hypertension [6]. Furthermore, treat-
ment of animals after onset of hypertension reduced vascular
oxidative stress, improved NO-mediated vasodilatation and re-
duced blood pressure [6]. Meanwhile, we do not know if other
mitochondria targeted nitroxides will reduce blood pressure or
antihypertensive effect is speciﬁc to mitoTEMPO. We therefore
performed additional studies in which mCP1 and mCP2 were ad-
ministered after the onset of angiotensin II-induced hypertension.
Following 9 days of angiotensin II infusion (0.7 mg/kg/day) systolicblood pressure reached 150 mm Hg (Fig. 6A). The subsequent
addition of mCP1 or mCP2 (1.4 mg/kg/day) using osmotic mini-
pump resulted in a time-dependent decrease of blood pressure.
Infusion of mCP1 and mCP2 signiﬁcantly reduced blood pressure
to 133 7 5 mm Hg and 129 7 6 mm Hg while blood pressure in
mice infused with saline (vehicle) have continued to rise and
reached 163 7 5 mm Hg at day 14 (Fig. 6A). Of note, treatment of
healthy control mice with mitochondria targeted nitroxides did
not affect basal blood pressure (101 mm Hg) because O2−• does
play a role in the regulation of blood pressure in normotensive
subjects [6]. These data indicate that mCP1 and mCP2 provide
antihypertensive effect similar to mitoTEMPO which we have
previously described [6].
In order to compare time-dependent antihypertensive effects
of mitochondria-targeted nitroxides we have treated hypertensive
mice with daily i.p. injection of saline (vehicle), or 1.4 mg/kg mCP1,
mCP2 or mitoTEMPO and measured blood pressure before and
after injection. It was found that i.p. treatment with nitroxides
acutely reduced blood pressure however this antihypertensive
effect was slightly reduced next day after injection (Fig. 6B).
Meanwhile the daily treatments increased antihypertensive
effect in a time-dependent ﬁssion. Interestingly, i.p. treatment
with mCP1 and mCP2 provide antihypertensive effect similar to
mitoTEMPO (Fig. 6B).
The above studies showing that mCP1 and mCP1 can reduce
hypertension do not provide insight into whether anti-
hypertensive effect was associated with reduced O2−• level and
improved vascular function. Therefore, additional studies were
performed of the antioxidant effects of mCP1 and mCP2. Vas-
cular O2−• production in isolated aortic vessels from hypertensive
90
100
110
120
130
140
150
160
170
180
8 10 12 14 16
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 m
m
 H
g
Ang II
Ang II + mCP1
Control
Ang II + mCP2
mCP1
mCP
mCP2
**
*
Angiotensin II infusion, days
80
90
100
110
120
130
140
150
160
170
180
9th day 60min
after i.p.
10th day 60min
after i.p.
11th day 60min
after i.p.
12th day 60min
after i.p.
13th day 60min
after i.p.
14th day 60min
after i.p.
AngII+Saline
AngII+mT
AngII+mCP1
AngII+mCP2
Control
mT
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 m
m
 H
g
**
*
A B
Fig. 6. Antihypertensive effect of mitochondria targeted nitroxides in angiotensin II-infused mice. (A) Mice were implanted with osmotic pumps after onset of hypertension
containing 1.4 mg/kg/day nitroxide or saline as a vehicle. (B) Mice were treated with the i.p. injection of 1.4 mg/kg/day mCP1, mCP2 or mitoTEMPO (mT). Results represent
mean 7 SEM for 3–6 animals per group. nP o 0.001 vs control, nnP o 0.01 vs Ang II.
A.E. Dikalova et al. / Redox Biology 4 (2015) 355–362360mice after onset of angiotensin II induced hypertension was
measured using ﬂuorescent probe DHE and HPLC analysis of O2−•
speciﬁc product 2-hydroxyethidium (Fig. 7A) [32]. Both mCP1 and
mCP2 reduced vascular O2−• and blood pressure similarly to pre-
viously report for mitoTEMPO [6] which support pharmacological
activity in treatment of vascular oxidative stress by proxyl-based
mitochondria-targeted antioxidants.
Increased O2−• production in vessels is leading to inactivation of
endothelial nitric oxide and vasoconstriction which contributes to
hypertension [30]. We hypothesized that mitochondria-targeted
nitroxides will improve vascular nitric oxide level since these
treatments reduced vascular O2−•. In order test this hypothesis we
measured vascular nitric oxide in aortic vessels using electron spin
resonance and speciﬁc nitric oxide spin trap Fe(DETC)2 as we have
previously described [33]. It was found that treatment of hy-
pertensive mice treated with mCP1 or mCP2 prevented oxidation
of nitric oxide and signiﬁcantly improved vascular nitric oxide
level (Fig. 7B).0
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In this work we have synthesized novel proxyl-based mi-
tochondria-targeted nitroxides mCP1 and mCP2 and studied their
antioxidant properties. The cellular penetration of these nitroxides
is driven by the lipophilic triphenyl cation and therefore it is likely
to be similar for proxyl and TEMPO based mitochondria targeted
nitroxides. Our data however show signiﬁcant difference in the
intracellular reduction of mCP1, mCP2 and mitoTEMPO (Fig. 5).
These nitroxides were present in intact cells at higher concentra-
tion compared with mitoTEMPO (Fig. 4A) which is in line with
greater bioreduction resistance of proxyl based nitroxides (Fig. 5).
The advantageous cellular accumulation of mCP1 and mCP2
however was counteracted by reduced reactivity with O2−• com-
pared with mitoTEMPO (Fig. 3) which can eliminate the potential
advantages of proxyl-based nitroxides. Indeed, both proxyl- and
TEMPO-based mitochondria targeted nitroxides showed similar
protection of respiration in H2O2-treated endothelial cells (Fig. 4).
Furthermore, our in vivo study in angiotensin II-infused miceAngII+mCP1 mCP2 AngII+mCP2
****
A
B
****
AngII+mCP1 mCP2 AngII+mCP2
mCP1 and mCP2 after onset of angiotensin II-induced hypertension using osmotic
14-days angiotensin II infusion. (B) Detection of endothelial nitric oxide in aortas
ean 7 SEM for 5–8 animals per group. nP o 0.01 vs control, nnP o 0.05 vs AngII.
A.E. Dikalova et al. / Redox Biology 4 (2015) 355–362 361showed that antihypertensive and antioxidant effects of mCP1 and
mCP2 were not signiﬁcantly different from mito-TEMPO (Figs. 6
and 7). Our data also show that mitoTEMPO is not the only mi-
tochondria-targeted nitroxide exhibiting antihypertensive effect
and studies of analogs such as mCP1 and mCP2 may help in op-
timization of chemical structure of mitochondria-targeted nitr-
oxides for improved, lipophility, antioxidant efﬁcacy and
pharmacokinetics.
Antihypertensive effects of TEMPOL and other untargeted
nitroxides has been previously shown [34]. Acute treatment of
hypertensive animals with TEMPOL caused dose-dependent re-
ductions in blood pressure which was accompanied with vasodi-
lation, increased nitric oxide, reduced sympathetic activity and
enhanced potassium channel conductance in blood vessels
and neurons [34]. We have proposed that mitochondria-targeted
SOD mimetic will speciﬁcally reduce mitochondrial O2−• and re-
duce vascular oxidative stress and improve endothelium depen-
dent relaxation. Indeed, we have previously demonstrated that
mitoTEMPO attenuated hypertension in dose-dependent manner,
reduced production of mitochondrial O2−• and H2O2, increased
endothelial NO and improved vasodilatation while similar dose of
TEMPOL was not effective [6]. Importantly, we found that targeting
of SOD mimetic to mitochondria provided beneﬁcial effects at a
dose 1000-fold lower than previously reported for TEMPOL [6]. In
this work we show similar activity of other mitochondria-targeted
mCP1 and mCP2 therefore representing new antihypertensive
agents that could add to the currently available therapeutic
armamentarium.
These studies conﬁrmed an important role of mitochon-
drial O2−• in the hypertension and demonstrated that mitochon-
dria-targeted nitroxides could have therapeutic beneﬁt in treat-
ment of hypertension.Acknowledgments
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